Literature DB >> 27858936

Retinal ganglion cell and axonal loss in optic neuritis: risk factors and visual functions.

T H Lee1, Y S Ji1, S W Park1, H Heo1.   

Abstract

PurposeThe peripapillary retinal nerve fiber layer (pRNFL) and the macular ganglion cell-inner plexiform layer (GCIPL) are important predictive factors for the prognosis of optic neuritis (ON). We investigated the risk factors for pRNFL and GCIPL thinning in ON and its relationship with visual function.Patients and methodsWe analyzed 33 eyes of 33 patients with a first attack of unilateral ON. Patients were divided into two groups according to pRNFL and GCIPL thinning, using spectral-domain optical coherence tomography. We evaluated patients' age, sex, color vision, visual acuity (VA), optic nerve findings on MRI, elapsed period from onset of visual symptoms to steroid treatment, visual field (VF) mean deviation (MD), average pRNFL thickness, and GCIPL thickness.ResultsThere was no patient with residual VF defect in the groups without pRNFL or GCIPL thinning. Significant correlations were found between pRNFL (some sectors) and GCIPL (all sectors) thickness and BCVA and VF MD (P<0.03 for all). Multivariate logistic regression analysis revealed that only worse initial VF MD was a significant risk factor of pRFNL and GCIPL thinning after ON (OR, 0.841; 95% CI, 0.730-0.970; P=0.017 and OR, 0.871; 95% CI, 0.761-0.998; P=0.046, respectively).ConclusionRetinal ganglion cell and axonal losses occurred in ON cases showing severe initial VF loss. Therefore, it is necessary to pay more attention to the degree of initial VF loss in ON while considering the possibility of residual VF loss accompanying pRNFL and GCIPL thinning.

Entities:  

Mesh:

Year:  2016        PMID: 27858936      PMCID: PMC5350374          DOI: 10.1038/eye.2016.253

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  32 in total

1.  In vivo assessment of retinal neuronal layers in multiple sclerosis with manual and automated optical coherence tomography segmentation techniques.

Authors:  Michaela A Seigo; Elias S Sotirchos; Scott Newsome; Aleksandra Babiarz; Christopher Eckstein; E'tona Ford; Jonathan D Oakley; Stephanie B Syc; Teresa C Frohman; John N Ratchford; Laura J Balcer; Elliot M Frohman; Peter A Calabresi; Shiv Saidha
Journal:  J Neurol       Date:  2012-03-15       Impact factor: 4.849

2.  Ganglion cell loss in relation to visual disability in multiple sclerosis.

Authors:  Scott D Walter; Hiroshi Ishikawa; Kristin M Galetta; Reiko E Sakai; Daniel J Feller; Sam B Henderson; James A Wilson; Maureen G Maguire; Steven L Galetta; Elliot Frohman; Peter A Calabresi; Joel S Schuman; Laura J Balcer
Journal:  Ophthalmology       Date:  2012-02-23       Impact factor: 12.079

3.  Acute optic neuritis: retinal ganglion cell loss precedes retinal nerve fiber thinning.

Authors:  Yu-Min Huang-Link; Abbas Al-Hawasi; Hans Lindehammar
Journal:  Neurol Sci       Date:  2014-10-14       Impact factor: 3.307

4.  Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness.

Authors:  Shiv Saidha; Stephanie B Syc; Mary K Durbin; Christopher Eckstein; Jonathan D Oakley; Scott A Meyer; Amy Conger; Teresa C Frohman; Scott Newsome; John N Ratchford; Elliot M Frohman; Peter A Calabresi
Journal:  Mult Scler       Date:  2011-08-24       Impact factor: 6.312

5.  Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis.

Authors:  M L Baier; G R Cutter; R A Rudick; D Miller; J A Cohen; B Weinstock-Guttman; M Mass; L J Balcer
Journal:  Neurology       Date:  2005-03-22       Impact factor: 9.910

Review 6.  Neurophysiological evidence for long-term repair of MS lesions: implications for axon protection.

Authors:  Steve J Jones; Adriana Brusa
Journal:  J Neurol Sci       Date:  2003-02-15       Impact factor: 3.181

7.  Timing of corticosteroid therapy is critical to prevent retinal ganglion cell loss in experimental optic neuritis.

Authors:  Mahasweta Dutt; Philomela Tabuena; Elvira Ventura; Abdolmohamad Rostami; Kenneth S Shindler
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-11-05       Impact factor: 4.799

8.  A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group.

Authors:  R W Beck; P A Cleary; M M Anderson; J L Keltner; W T Shults; D I Kaufman; E G Buckley; J J Corbett; M J Kupersmith; N R Miller
Journal:  N Engl J Med       Date:  1992-02-27       Impact factor: 91.245

9.  Optic neuritis in Singapore.

Authors:  S A Lim; K Y Goh; S Tow; E Fu; T Y Wong; A Seah; C Tan; J F Cullen
Journal:  Singapore Med J       Date:  2008-09       Impact factor: 1.858

10.  Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis.

Authors:  S Anand Trip; Patricio G Schlottmann; Stephen J Jones; Daniel R Altmann; David F Garway-Heath; Alan J Thompson; Gordon T Plant; David H Miller
Journal:  Ann Neurol       Date:  2005-09       Impact factor: 10.422

View more
  4 in total

1.  Risk of Autoimmune Diseases Following Optic Neuritis: A Nationwide Population-Based Cohort Study.

Authors:  Kevin Sheng-Kai Ma; Chee-Ming Lee; Po-Hung Chen; Yan Yang; Yi Wei Dong; Yu-Hsun Wang; James Cheng-Chung Wei; Wen Jie Zheng
Journal:  Front Med (Lausanne)       Date:  2022-06-13

2.  Pupillary light reflex in ethambutol-induced optic neuropathy.

Authors:  Yung-Ju Yoo; Jeong-Min Hwang; Hee Kyung Yang
Journal:  Sci Rep       Date:  2020-12-10       Impact factor: 4.379

3.  Neuroprotective Effects of Novel Treatments on Acute Optic Neuritis-A Meta-Analysis.

Authors:  Tsung-Hsien Tsai; Chao-Wen Lin; Li-Wei Chan; Teck-Boon Tew; Ta-Ching Chen
Journal:  Biomedicines       Date:  2022-01-17

4.  Altered Small-World Functional Network Topology in Patients with Optic Neuritis: A Resting-State fMRI Study.

Authors:  Ke Song; Juan Li; Yuanqiang Zhu; Fang Ren; Lingcan Cao; Zi-Gang Huang
Journal:  Dis Markers       Date:  2021-06-14       Impact factor: 3.434

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.